Caribou Biosciences Inc. announced that new clinical data from its allogeneic CAR-T cell therapy programs will be presented at the 2026 Tandem Meetings of ASTCT® and CIBMTR®, taking place from February 4-7 in Salt Lake City, Utah. The company will present updated clinical and translational data for vispa-cel (CB-010) from the ANTLER phase 1 trial in relapsed or refractory B cell non-Hodgkin lymphoma, as well as for CB-011 from the CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma. The CaMMouflage study data will be presented in an oral session and demonstrate a correlation between CAR-T cell expansion and deep, durable responses, supporting the regimen selected for dose expansion. These results were previously disclosed in November 2025 and will be presented with new supportive data during the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648550-en) on February 04, 2026, and is solely responsible for the information contained therein.